|
| Press Releases |
|
 |
|
| Wednesday, July 22, 2020 |
|
|
Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer's Disease and Dementia at the Alzheimer's Association International Conference (AAIC) 2020 |
| Eisai Co., Ltd. announced today that the company will conduct a total of 9 presentations, including the latest data of the investigational anti-amyloid beta (Aβ) protofibril antibody BAN2401, at the Alzheimer's Association International Conference (AAIC) to be held virtually from July 27 to 31, 2020. more info >> |
|
| Monday, July 20, 2020 |
|
|
Eisai: Smartphone App for Vital Signs Measurement of Patients With the Novel Coronavirus Infection Experimental Study Project Adopted as AMED Project |
| Allm Inc., Tokyo Medical and Dental University and Eisai Co., Ltd. announced that their jointly submitted study and development project has been selected by the Japan Agency for Medical Research and Development (AMED). more info >> |
|
| Tuesday, July 14, 2020 |
|
|
Eisai: Initiation of New Phase III Clinical Study (Ahead 3-45) of ban2401 Preclinical (Asymptomatic) Alzheimer's Disease |
| The AHEAD 3-45 will be conducted in the US, Japan, Canada, Australia, Singapore, and Europe. more info >> |
|
| Monday, July 13, 2020 |
|
|
Eisai: Industry-Academia-Government Joint Development Agreement Aiming for Drug Discovery for Systemic Lupus Erythematosus by Practical Application of Toll-Like Receptor Research Concluded |
| Eisai Co., Ltd. announced today that it has entered into an industry-academia-government joint research agreement with four universities in Japan concerning the "Industrialization of Japan-originated Toll-like receptor research by Academia-Industry collaborating All-Japan system: Creation of new drug for SLE treatment", which is a research project with Eisai as the representative research organization. more info >> |
|
| Thursday, July 9, 2020 |
|
|
Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer's Disease |
| Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that Biogen has completed the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the approval of aducanumab, an investigational treatment for Alzheimer's disease. more info >> |
|
|
Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma |
| Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding Eisai's and Merck's applications seeking accelerated approval of LENVIMA. more info >> |
|
| Wednesday, July 8, 2020 |
|
|
Eisai: New Drug Application for In-House Developed New Anti-insomnia Drug Dayvigo Accepted in Hong Kong |
| Eisai Co., Ltd. announced today that the new drug application for approval of its in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance, has been accepted by the Hong Kong Department of Health. more info >> |
|
|
Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Tazemetostat for EZH2 Gene Mutation-Positive Follicular Lymphoma |
| Eisai Co., Ltd. announced today that it has submitted a marketing authorization application in Japan for the EZH2 inhibitor tazemetostat hydrobromide (generic name, development code: E7438, "tazemetostat") for EZH2 gene mutation-positive follicular lymphoma. more info >> |
|
| Monday, July 6, 2020 |
|
|
Eisai to Launch In-House Developed New Anti-insomnia Drug Dayvigo (Lemborexant) with Indication for Insomnia in Japan |
| Eisai Co., Ltd. announced today that it has launched its in-house-discovered and developed orexin receptor antagonist DAYVIGO 2.5 mg, 5 mg, 10 mg tablets (lemborexant) for treatment of insomnia in Japan on July 6, 2020. more info >> |
|
|
Eisai: New Fine Granule Formulation of Anti-epileptic Drug Fycompa Launched in Japan |
| Eisai Co., Ltd. announced today that it has launched a new fine granule formulation of its in-house-discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) in Japan on July 6, 2020. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
U.S. Polo Assn. Celebrates Launch of Field X Fashion, Issue 2, Brand's Award-Winning Global, Digital Magazine Celebrating Sport and Fashion
Apr 15, 2025 22:07 HKT/SGT
|
|
|
Ausnutria Delivers Resilient Dual Growth in Revenue and Profit in 2024 
Apr 15, 2025 22:06 HKT/SGT
|
|
|
Bahrain Launches Informational Website and Hotline for the Golden Residency to Attract Global Professionals and Investors
Apr 15, 2025 22:06 HKT/SGT
|
|
|
TransNusa Becomes First Indonesian Airline to Launch Scheduled Bali - Guangzhou Route
Apr 15, 2025 22:05 HKT/SGT
|
|
|
Berberine Ursodeoxycholate (HTD1801) Consistently Demonstrates Comprehensive Benefits for Patients with Type 2 Diabetes Mellitus, Approaching NDA
Apr 15, 2025 22:04 HKT/SGT
|
|
|
Euro Manganese Announces Early Appointment of Chairman and Provides Financing Update
Apr 15, 2025 20:42 HKT/SGT
|
|
|
Kincora Copper: Second Major Earn-In Secured with AngloGold Ashanti
Apr 15, 2025 20:09 HKT/SGT
|
|
|
Standard Chartered GBA Business Confidence Survey shows calm before tariff storm in Q1
Apr 15, 2025 18:57 HKT/SGT
|
|
|
Kincora Copper: Investor Briefing Webinar - Sixth Asset Level Agreement
Apr 15, 2025 18:09 HKT/SGT
|
|
|
CTF Life Supports 10 Local Schools with Donations of Dr MAC Classroom Reading Programme and Learning Living Chinese Programme
Apr 15, 2025 17:52 HKT/SGT
|
|
|
Isuzu and Fujitsu sign partnership agreement to commercialize software defined vehicles
Apr 15, 2025 12:29 JST
|
|
|
MHI Awarded a Study on CO2 Capture Modules for FPSOs
Apr 15, 2025 10:46 JST
|
|
|
3rd ASEAN Procurement Innovation Summit & Awards 2025 - The Next Frontier in Procurement Excellence
Apr 14, 2025 23:19 HKT/SGT
|
|
|
Global strategic speakers confirmed to accelerate energy transformation at Japan Energy Summit & Exhibition 2025
Apr 14, 2025 23:00 HKT/SGT
|
|
|
Guangdong Syntrust GK Testing and Certification Tech Service Center Co., Ltd. Announces the First Annual Results after Listing, with a Significant Increase of 33.16% in Revenue
Apr 14, 2025 19:41 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
